• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在加拿大环境中整合个性化医疗:促进肿瘤临床研究的努力。

Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.

作者信息

Syme Rachel, Carleton Bruce, Leyens Lada, Richer Etienne

机构信息

CIHR Institute of Cancer Research, Calgary, Alta., Canada.

出版信息

Public Health Genomics. 2015;18(6):372-80. doi: 10.1159/000441560. Epub 2015 Nov 14.

DOI:10.1159/000441560
PMID:26565702
Abstract

There is currently a rapid evolution of clinical practices based on the introduction of patient stratification and molecular diagnosis that is likely to improve health outcomes. Building on a strong research base, complemented by strong support from clinicians and health authorities, the oncology field is at the forefront of this evolution. Yet, clinical research is still facing many challenges that need to be addressed in order to conduct necessary studies and effectively translate medical breakthroughs based on personalized medicine into standards of care. Leveraging its universal health care system and on resources developed to support oncology clinical research, Canada is well positioned to join the international efforts deployed to address these challenges. Available resources include a broad range of structures and funding mechanisms, ranging from direct clinical trial support to post-marketing surveillance. Here, we propose a clinical model for the introduction of innovation for precision medicine in oncology that starts with patients' and clinicians' unmet needs to initiate a cycle of discovery, validation, translation and sustainability development.

摘要

目前,基于患者分层和分子诊断的引入,临床实践正在迅速发展,这可能会改善健康结果。肿瘤学领域在强大的研究基础之上,再加上临床医生和卫生当局的大力支持,处于这一发展的前沿。然而,临床研究仍面临许多挑战,为了开展必要的研究并有效地将基于个性化医疗的医学突破转化为护理标准,这些挑战需要得到解决。利用其全民医疗保健系统以及为支持肿瘤学临床研究而开发的资源,加拿大完全有能力参与为应对这些挑战而开展的国际努力。可用资源包括广泛的结构和资助机制,从直接的临床试验支持到上市后监测。在此,我们提出一种临床模式,用于在肿瘤学中引入精准医学创新,该模式从患者和临床医生未满足的需求出发,启动一个发现、验证、转化和可持续发展的循环。

相似文献

1
Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research.在加拿大环境中整合个性化医疗:促进肿瘤临床研究的努力。
Public Health Genomics. 2015;18(6):372-80. doi: 10.1159/000441560. Epub 2015 Nov 14.
2
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).个性化医学和肿瘤免疫时代临床试验的变化:国际肿瘤学和血液肿瘤学临床试验大会(ICTO 2017)报告。
J Exp Clin Cancer Res. 2017 Dec 28;36(1):192. doi: 10.1186/s13046-017-0668-0.
3
Cancer genomics and clinical practice: how can we close the gap more quickly?癌症基因组学与临床实践:我们如何能更快缩小差距?
Curr Opin Obstet Gynecol. 2017 Feb;29(1):1-3. doi: 10.1097/GCO.0000000000000341.
4
From Illumination to Innovation: Visualizing the Future-The 2015 Presidential Address.从照明到创新:展望未来——2015年主席致辞
J Clin Oncol. 2016 Aug 10;34(23):2679-83. doi: 10.1200/JCO.2016.68.6923. Epub 2016 Jun 27.
5
US Cancer Moonshot must strike a balance between research and prevention.美国癌症“登月计划”必须在研究与预防之间找到平衡。
Nature. 2016 Nov 24;539(7630):467. doi: 10.1038/539467a.
6
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.《2017年临床癌症进展:美国临床肿瘤学会抗癌进展年度报告》
J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1.
7
Clinical trials in the era of personalized oncology.个体化肿瘤学时代的临床试验。
CA Cancer J Clin. 2011 Nov-Dec;61(6):365-81. doi: 10.3322/caac.20135. Epub 2011 Oct 27.
8
Integrating precision cancer medicine into healthcare-policy, practice, and research challenges.将精准癌症医学融入医疗政策、实践和研究面临挑战。
Genome Med. 2016 Oct 24;8(1):108. doi: 10.1186/s13073-016-0362-4.
9
Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.进行检测的原因:常规肿瘤学实践中复杂分子谱分析的开端。
Ann Oncol. 2019 Nov 1;30(11):1691-1694. doi: 10.1093/annonc/mdz392.
10
Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.临床实施策略:三家不同机构的精准肿瘤学。
Health Aff (Millwood). 2018 May;37(5):751-756. doi: 10.1377/hlthaff.2017.1575.

引用本文的文献

1
Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm.将精准肿瘤学作为标准治疗模式在全系统应用面临的挑战与解决方案。
Camb Prism Precis Med. 2024 Mar 26;2:e4. doi: 10.1017/pcm.2024.1. eCollection 2024.
2
A survey of experts on personalized medicine landscape in European Union and China.对欧盟和中国个性化医学领域专家的调查。
BMC Health Serv Res. 2023 May 23;23(1):517. doi: 10.1186/s12913-023-09471-y.
3
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.
个性化医学的融资和报销模式:系统评价以确定当前模式和未来选择。
Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4.